المؤلفون: Fang F; School of Pharmacy, Wannan Medical College, Wuhu, 241002, People's Republic of China., Chen YY; School of Pharmacy, Wannan Medical College, Wuhu, 241002, People's Republic of China., Zhang XM; School of Chemistry and Materials Science, Anhui Normal University, Wuhu, 241002, People's Republic of China., Tang J; School of Pharmacy, Wannan Medical College, Wuhu, 241002, People's Republic of China., Liu YH; School of Pharmacy, Wannan Medical College, Wuhu, 241002, People's Republic of China., Peng CS; School of Pharmacy, Wannan Medical College, Wuhu, 241002, People's Republic of China., Sun Y; School of Pharmacy, Wannan Medical College, Wuhu, 241002, People's Republic of China.; Institute of Synthesis and Application of Medical Materials, Wannan Medical College, Wuhu, 241002, People's Republic of China.

المصدر: International journal of nanomedicine [Int J Nanomedicine] 2024 Sep 18; Vol. 19, pp. 9689-9705. Date of Electronic Publication: 2024 Sep 18 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101263847 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2013 (Electronic) Linking ISSN: 11769114 NLM ISO Abbreviation: Int J Nanomedicine Subsets: MEDLINE

مواضيع طبية MeSH: ErbB Receptors*/metabolism , Colorectal Neoplasms*/therapy , Colorectal Neoplasms*/drug therapy , Irinotecan*/pharmacology , Irinotecan*/chemistry , Irinotecan*/pharmacokinetics , Irinotecan*/administration & dosage , Nanoparticles*/chemistry , Cetuximab*/chemistry , Cetuximab*/pharmacology , Cetuximab*/pharmacokinetics , Photothermal Therapy*/methods , Indocyanine Green*/chemistry , Indocyanine Green*/pharmacokinetics , Indocyanine Green*/pharmacology , Indocyanine Green*/administration & dosage, Animals ; Humans ; Cell Line, Tumor ; Mice ; Mice, Nude ; Polyethylene Glycols/chemistry ; Mice, Inbred BALB C ; Camptothecin/chemistry ; Camptothecin/pharmacology ; Camptothecin/pharmacokinetics ; Camptothecin/administration & dosage ; Drug Carriers/chemistry ; Polymers/chemistry ; Infrared Rays ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/administration & dosage ; Lecithins/chemistry ; Xenograft Model Antitumor Assays ; Lipids/chemistry

المؤلفون: Zhu Q; School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.; State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China., Zhang R; School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China., Gu X; School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China., Zhao Z; State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China., Gao Q; School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.; State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China., Chen M; State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China., Wu Q; State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China., Xie T; School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.; State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China., Sui X; School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.; State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China.; Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.

المصدر: Theranostics [Theranostics] 2024 Aug 26; Vol. 14 (14), pp. 5443-5460. Date of Electronic Publication: 2024 Aug 26 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101552395 Publication Model: eCollection Cited Medium: Internet ISSN: 1838-7640 (Electronic) Linking ISSN: 18387640 NLM ISO Abbreviation: Theranostics Subsets: MEDLINE

مواضيع طبية MeSH: Cetuximab*/pharmacology , Cetuximab*/therapeutic use , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/metabolism , Proto-Oncogene Proteins p21(ras)*/genetics , Proto-Oncogene Proteins p21(ras)*/metabolism , Lignans*/pharmacology , Lignans*/therapeutic use , Biphenyl Compounds*/pharmacology , Biphenyl Compounds*/therapeutic use , Mutation* , Cell Proliferation*/drug effects , Apoptosis*/drug effects, Humans ; Animals ; Cell Line, Tumor ; Mice ; Xenograft Model Antitumor Assays ; Proto-Oncogene Mas ; Drug Synergism ; Mice, Nude ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Mice, Inbred BALB C ; Allyl Compounds ; Phenols

المؤلفون: Samalin E; Oncology Department, Institut du Cancer de Montpellier, Univ. Montpellier (ICM), 208 avenue des Apothicaires, Montpellier 34298, France; Institut de Génomique Fonctionnelle, CNRS, INSERM, Univ. Montpellier, Montpellier, France. Electronic address: emmanuelle.samalin@icm.unicancer.fr., Mazard T; Oncology Department, Institut du Cancer de Montpellier, Univ. Montpellier (ICM), 208 avenue des Apothicaires, Montpellier 34298, France; Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Univ Montpellier, Montpellier, France., Assenat E; Oncology Department, Institut du Cancer de Montpellier, Univ. Montpellier (ICM), 208 avenue des Apothicaires, Montpellier 34298, France; Digestive Oncology Department, CHU Montpellier, Univ. Montpellier, Montpellier, France., Rouyer M; INSERM CIC-P 1401, Univ. Bordeaux, Bordeaux PharmacoEpi, Bordeaux 33000, France., de la Fouchardière C; Medical Oncology Department, Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France; Cancer Research Center of Lyon (CRCL), UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France., Guimbaud R; Medical Oncology Department, CHU Toulouse, Toulouse, France., Smith D; Digestive Oncology, Centre Medico-Chirurgical Magellan, Hopital Haut-Leveque, CHU de Bordeaux, Bordeaux, France., Portales F; Oncology Department, Institut du Cancer de Montpellier, Univ. Montpellier (ICM), 208 avenue des Apothicaires, Montpellier 34298, France., Ychou M; Oncology Department, Institut du Cancer de Montpellier, Univ. Montpellier (ICM), 208 avenue des Apothicaires, Montpellier 34298, France., Adenis A; Oncology Department, Institut du Cancer de Montpellier, Univ. Montpellier (ICM), 208 avenue des Apothicaires, Montpellier 34298, France., Fiess C; Clinical Research and Innovation Department, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France., Lopez-Crapez E; Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Univ Montpellier, Montpellier, France; Translational Research Unit, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France., Thezenas S; Biometrics Unit, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France.

المصدر: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2024 Aug; Vol. 56 (8), pp. 1375-1381. Date of Electronic Publication: 2024 Jan 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 100958385 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3562 (Electronic) Linking ISSN: 15908658 NLM ISO Abbreviation: Dig Liver Dis Subsets: MEDLINE

مواضيع طبية MeSH: Cetuximab*/administration & dosage , Cetuximab*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/pathology , Irinotecan*/therapeutic use , Irinotecan*/administration & dosage , Leucovorin*/therapeutic use , Leucovorin*/administration & dosage , Fluorouracil*/administration & dosage , Fluorouracil*/therapeutic use , Oxaliplatin*/therapeutic use , Oxaliplatin*/administration & dosage, Humans ; Male ; Middle Aged ; Female ; Retrospective Studies ; Aged ; Adult ; Progression-Free Survival ; Liver Neoplasms/secondary ; Liver Neoplasms/drug therapy ; Liver Neoplasms/genetics ; Proto-Oncogene Proteins B-raf/genetics ; Mutation

المؤلفون: Tanaka R; Department of Otolaryngology-Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-Ku, Niigata, 950-8510, Japan.; Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan., Ueki Y; Department of Otolaryngology-Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-Ku, Niigata, 950-8510, Japan. ucuekin@gmail.com., Ohshima S; Department of Otolaryngology-Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-Ku, Niigata, 950-8510, Japan., Omata J; Department of Otolaryngology-Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-Ku, Niigata, 950-8510, Japan., Yokoyama Y; Department of Otolaryngology-Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-Ku, Niigata, 950-8510, Japan., Takahashi T; Department of Otolaryngology-Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-Ku, Niigata, 950-8510, Japan., Shodo R; Department of Otolaryngology-Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-Ku, Niigata, 950-8510, Japan., Yamazaki K; Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan., Ohtaki K; Department of Otolaryngology-Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-Ku, Niigata, 950-8510, Japan.; Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan., Togashi T; Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan., Horii A; Department of Otolaryngology-Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-Ku, Niigata, 950-8510, Japan.

المصدر: International journal of clinical oncology [Int J Clin Oncol] 2024 Aug; Vol. 29 (8), pp. 1133-1141. Date of Electronic Publication: 2024 May 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Cetuximab*/administration & dosage , Cetuximab*/adverse effects , Cetuximab*/therapeutic use , Carboplatin*/administration & dosage , Carboplatin*/therapeutic use , Carboplatin*/adverse effects , Neoadjuvant Therapy* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Paclitaxel*/administration & dosage , Paclitaxel*/therapeutic use , Paclitaxel*/adverse effects , Squamous Cell Carcinoma of Head and Neck*/drug therapy , Squamous Cell Carcinoma of Head and Neck*/pathology , Squamous Cell Carcinoma of Head and Neck*/mortality , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/pathology, Humans ; Aged ; Male ; Female ; Retrospective Studies ; Middle Aged ; Aged, 80 and over ; Adult

المؤلفون: Chu L; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, China; Yantai Laishan Fourth People's Hospital, Yantai, 264003, China., Sun Y; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, China., Zhao Y; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, China., Wang A; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, China. Electronic address: wangaipingytu@163.com., Sun Y; Shandong Business Institute, Yantai, 264670, China., Duan X; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, China., Li N; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, China., Xia H; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, China., Liu W; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, China., Sun K; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, China; National Key Laboratory of Advanced Drug Delivery and Release Systems, Novapath Pharma (Chengdu) Co., Ltd., Chengdu, Sichuan 610200, China. Electronic address: sunkx@ytu.edu.cn.

المصدر: International journal of pharmaceutics [Int J Pharm] 2024 Jul 20; Vol. 660, pp. 124262. Date of Electronic Publication: 2024 May 28.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE

مواضيع طبية MeSH: Doxorubicin*/administration & dosage , Doxorubicin*/pharmacology , Doxorubicin*/pharmacokinetics , Exosomes*/metabolism , Glioblastoma*/drug therapy , Glioblastoma*/metabolism , Glioblastoma*/pathology , Cetuximab*/administration & dosage , Cetuximab*/pharmacology , Brain Neoplasms*/drug therapy , Brain Neoplasms*/metabolism , Blood-Brain Barrier*/metabolism, Animals ; Humans ; Cell Line, Tumor ; Rats ; Drug Delivery Systems/methods ; Male ; Brain/metabolism ; Rats, Sprague-Dawley ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Rats, Nude

المؤلفون: Vitale P; Oncology Operative Unit, Hospital of Frattamaggiore, Frattamaggiore, Italy., De Falco V; Oncology Operative Unit, Hospital of Frattamaggiore, Frattamaggiore, Italy., Addeo R; Oncology Operative Unit, Hospital of Frattamaggiore, Frattamaggiore, Italy.

المصدر: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Jul; Vol. 24 (7), pp. 481-484. Date of Electronic Publication: 2024 May 13.

نوع المنشور: Editorial

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Cetuximab*/administration & dosage , Cetuximab*/pharmacology , Neoplasm Recurrence, Local*/drug therapy , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/pathology , Antineoplastic Agents, Immunological*/administration & dosage , Antineoplastic Agents, Immunological*/pharmacology , Neoplasm Metastasis*, Humans

المؤلفون: Nguyen A; Department of Bioengineering, University of Texas at Dallas, Richardson 75080-3021, Texas, United States., Bhandari C; Department of Bioengineering, University of Texas at Dallas, Richardson 75080-3021, Texas, United States., Keown M; Department of Bioengineering, University of Texas at Dallas, Richardson 75080-3021, Texas, United States., Malkoochi A; Department of Bioengineering, University of Texas at Dallas, Richardson 75080-3021, Texas, United States., Quaye M; Department of Bioengineering, University of Texas at Dallas, Richardson 75080-3021, Texas, United States., Mahmoud D; Department of Bioengineering, University of Texas at Dallas, Richardson 75080-3021, Texas, United States., Shah N; Department of Bioengineering, University of Texas at Dallas, Richardson 75080-3021, Texas, United States., Alzhanova D; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas 75390-9096, Texas, United States., Cameron CG; Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington 76019, Texas, United States., Ferruzzi J; Department of Bioengineering, University of Texas at Dallas, Richardson 75080-3021, Texas, United States., McFarland SA; Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington 76019, Texas, United States., Shafirstein G; Department of Cell Stress Biology, Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo 14263, New York, United States., Brekken R; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas 75390-9096, Texas, United States.; Department of Surgery, Department of Pharmacology, Cancer Biology Graduate Program, University of Texas Southwestern Medical Center, Dallas 75390-8593, Texas, United States., Obaid G; Department of Bioengineering, University of Texas at Dallas, Richardson 75080-3021, Texas, United States.

المصدر: Molecular pharmaceutics [Mol Pharm] 2024 Jul 01; Vol. 21 (7), pp. 3296-3309. Date of Electronic Publication: 2024 Jun 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1543-8392 (Electronic) Linking ISSN: 15438384 NLM ISO Abbreviation: Mol Pharm Subsets: MEDLINE

مواضيع طبية MeSH: Photochemotherapy*/methods , Indoles*/chemistry , Cetuximab*/chemistry , Cetuximab*/pharmacology, Humans ; Cell Line, Tumor ; Head and Neck Neoplasms/drug therapy ; Photosensitizing Agents/chemistry ; Benzenesulfonates

المؤلفون: Desilets A; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States. Electronic address: desilea@mskcc.org., Pfister DG; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, United States., Stein S; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States., Wong W; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, United States., Sherman EJ; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, United States., Fetten J; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, United States., Hung TKW; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, United States., Kriplani A; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, United States., Dunn LA; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, United States., Ho AL; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, United States., Michel LS; Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, United States.

المصدر: Oral oncology [Oral Oncol] 2024 Jul; Vol. 154, pp. 106861. Date of Electronic Publication: 2024 May 24.

نوع المنشور: Journal Article; Clinical Trial, Phase I

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593 (Electronic) Linking ISSN: 13688375 NLM ISO Abbreviation: Oral Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Anilides*/therapeutic use , Anilides*/administration & dosage , Cetuximab*/therapeutic use , Cetuximab*/administration & dosage , Pyridines*/therapeutic use , Pyridines*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Squamous Cell Carcinoma of Head and Neck*/drug therapy, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Neoplasm Recurrence, Local/drug therapy ; Head and Neck Neoplasms/drug therapy ; Head and Neck Neoplasms/pathology ; Neoplasm Metastasis

المؤلفون: Tada M; Department of Chemical Science and Engineering, Tokyo Institute of Technology, 12-12-1-H101 Ookayama, Meguro, Tokyo, 152-8552, Japan., Kaizuka Y; Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan., Kannaka K; Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan., Suzuki H; Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan., Joho T; Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikariga-oka, Fukushima, 960-1295, Japan., Takahashi K; Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikariga-oka, Fukushima, 960-1295, Japan., Uehara T; Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan., Tanaka H; Faculty of Pharmacy, Juntendo University, 6-8-1 Hinode, Urayasu, Chiba, 279-0013, Japan.; Department of Chemical Science and Engineering, Tokyo Institute of Technology, 12-12-1-H101 Ookayama, Meguro, Tokyo, 152-8552, Japan.

المصدر: ChemMedChem [ChemMedChem] 2024 Sep 16; Vol. 19 (18), pp. e202400369. Date of Electronic Publication: 2024 Aug 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101259013 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1860-7187 (Electronic) Linking ISSN: 18607179 NLM ISO Abbreviation: ChemMedChem Subsets: MEDLINE

مواضيع طبية MeSH: Astatine*/chemistry , Cetuximab*/chemistry , Cetuximab*/pharmacology , Esters*/chemistry , Esters*/chemical synthesis, Animals ; Mice ; Humans ; Tissue Distribution ; Molecular Structure ; Radiopharmaceuticals/chemistry ; Radiopharmaceuticals/chemical synthesis ; Alpha Particles/therapeutic use ; Female

المؤلفون: Mercier L; Gustave Roussy, Department Of Medical Oncology, 94800 Villejuif, France. Electronic address: lea.mercier96@gmail.com., Delaye M; Gustave Roussy, Department Of Medical Oncology, 94800 Villejuif, France., Fuerea A; Gustave Roussy, Department Of Medical Oncology, 94800 Villejuif, France., Ducreux M; Gustave Roussy, Department Of Medical Oncology, 94800 Villejuif, France; Université Paris Saclay, 91400 Orsay, France., Boilève A; Gustave Roussy, Department Of Medical Oncology, 94800 Villejuif, France; Université Paris Saclay, 91400 Orsay, France.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Sep; Vol. 208, pp. 114193. Date of Electronic Publication: 2024 Jun 27.

نوع المنشور: Letter; Case Reports

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cetuximab*/administration & dosage , Cetuximab*/adverse effects , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology, Humans ; Male ; Administration, Oral ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Aged ; Female ; Intestinal Obstruction/etiology ; Middle Aged